Who is this trial for: This trial is for patients with one of three forms of non-small cell lung cancer (NSCLC) – ALK, ROS1, or RET - who are progressing on their current TKI under certain conditions, and are willing to try an experimental drug combination in order to extend the life of their current TKI.  Amivantamab is a bi-specific antibody targeting the cell survival pathways MET and EGFR.  The trial may be most appropriate for patients who are progressing without a targetable mutation or clearly identified driver of their cancer growth.   ..read more

Rich Gopen is an ALK patient and one of our match donors this Lung Cancer Awareness Month (LCAM), which means that whatever funds you donate or raise will be doubled thanks to Rich’s and others’ generous match donations. We interviewed him about his journey with ALK+ lung cancer, what motivates him, and his hopes for the future ..read more

Who is this trial for: NVL-655 is a 4th generation, brain-penetrant, ALK TKI inhibitor created to overcome several limitations observed with currently available therapies. NVL-655 is designed to have activity in tumors that have developed resistance to first, second, and third-generation ALK inhibitors, including tumors with the solvent front G1202R mutation or compound mutations G1202R/L1196M (“GRLM”), G1202R/G1269A (“GRGA”), or G1202R/L1198F (“GRLF”).  In other words, it is for patients for whom other ALK TKIs have failed under certain conditions.  ..read more

The clinical results from the Phase 1 portion of the ALKOVE-1 study is bringing new hope to patients with ALK-positive lung cancer, especially those who have exhausted other treatment options. NVL-655, a fourth-generation ALK inhibitor, has shown unique effectiveness in overcoming resistance to previous treatments, including those with brain metastases and specific resistance mutations ..read more

In recent years, the German patient network, ALKpositiv Deutschland, has become an important point of contact for patients with ALK-positive lung cancer in German-speaking countries. Our story began in 2019 with a Facebook group that served as a platform for those affected to exchange information. From the outset, this group was an important place to find out online about diagnoses, therapies, side effects and current research updates, and to provide mutual support ..read more

I was born and raised in Pennsylvania and had an interest in cancer research from the time that I was a child. I was exposed to Fox Chase Cancer Center very early on and knew from that moment that I wanted to do something to help in the fight against cancer. I attended University of the Sciences in Philadelphia for both my undergraduate and graduate degree as the school had a strong emphasis on the sciences and health professions ..read more

With over a decade of entrepreneurship and management experience, I’ve learned one enduring truth: obstacles become opportunities when met with hard work and dedication. Believing that anything is possible with perseverance and self-belief, I’ve discovered that the greatest gift is empowering others to believe in themselves as well ..read more

This pumpkin bread was such a huge hit on my Thanksgiving table years ago, that my family begins asking for it as soon as Fall begins.  I serve it with various jams, jellies and honey butter on my brunch tables too ..read more

For those facing the challenging diagnosis of ALK-positive lung cancer, brain metastases often pose a serious concern. Research reveals that up to 40% of these patients have brain metastases right from the start. This sets the stage for a critical question in treatment planning: Is it better to tackle these brain metastases with spot radiation, or stereotactic radiosurgery (SRS ..read more

If you think you don’t like eggplant this will change your mind. This recipe has all the feels. Warm, cheesy, melty, straight from the oven.  I make it with any ground meat I have on hand.  What’s also nice is that it’s baked and not fried. So you can have that second helping. You’ll want it.  ..read more